Soliris receives approval from Health Canada for ultra-rare aHUS

Alexion's drug Soliris (eculizumab) has received marketing approval from Health Canada for the treatment of patients with the ultra-rare and life-threatening genetic condition, atypical haemolytic uraemic syndrome (aHUS). aHUS causes abnormal clots to form in the blood vessels throughout the body, leading to progressive and catastrophic damage to the vital organs, including the kidneys, brain and heart. The pathogenesis of …